Compounds > 1,n(2)-ethenoguanosine
Page last updated: 2024-12-07

1,n(2)-ethenoguanosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,n(2)-ethenoguanosine is not a recognized or standard chemical name. It seems like there might be a typo or misunderstanding in the term.

Let's break down the parts:

* **1,n(2):** This likely refers to the position of a modification within a molecule. However, it's unclear what molecule is being referenced.
* **etheno:** This indicates a modification where a double bond (an ene group) has been added to the molecule.
* **guanosine:** This is a nucleoside, consisting of guanine (a purine base) attached to a ribose sugar.

**Potential interpretations and their research relevance:**

1. **Typo in the position:** It's possible there's a typo in the position 1,n(2).
* If it meant **1,N2-ethenoguanosine**: This would refer to a specific modification of guanosine, where an etheno group is added to the N2 position of the guanine base. This modification is significant because:
* **DNA damage marker:** 1,N2-ethenoguanosine is a major adduct formed in DNA upon exposure to certain carcinogens like vinyl chloride. It is used as a biomarker of exposure to these compounds.
* **Mutation potential:** This modification can cause mispairing during DNA replication, leading to mutations.
* **Research applications:** Researchers study 1,N2-ethenoguanosine to understand the mechanisms of DNA damage, mutagenesis, and carcinogenesis.

2. **Unconventional naming:** It's possible the term is not standard, and refers to a specific, less common, modification of guanosine.
* In this case, we'd need more information to determine the exact nature of the modification and its research relevance.

**To clarify the meaning, please provide the following information:**

* **Source of the term:** Where did you encounter this name?
* **Context:** What was the term referring to in that specific context?

Once we have more information, we can give you a more accurate and informative response.

1,N(2)-ethenoguanosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124923
CHEMBL ID610656
MeSH IDM0212751

Synonyms (9)

Synonym
62462-38-8
3-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-imidazo[1,2-a]purin-9-one
3-(d-ribofuranosyl)-3,4-dihydro-9h-imidazo[1,2-a]purin-9-one
CHEMBL610656
5,9-dihydro-9-oxo-3-beta-d-ribofuranosylimidazo(1,2-a)purine
3,4-dihydro-3-beta-d-ribofuranosyl-9h-imidazo(1,2-alpha)purine-9-one
1,n(2)-ethenoguanosine
9h-imidazo(1,2-alpha)purine-9-one, 3,4-dihydro-3-beta-d-ribofuranosyl-
DTXSID40276282
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID68266Concentration required to cause 50% reduction in cellular DNA synthesis in ESM cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68267Concentration required to cause a microscopically detectable alteration of normal cell morphology in ESM cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68269Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68268Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81055Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81047Concentration required to cause 50% reduction in HEL cell growth1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68272Concentration required to inhibit HSV-2(G) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68276Concentration required to inhibit VV induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68270Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81052Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81190Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81188Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68274Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68271Concentration required to inhibit HSV-2(196) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68275Concentration required to inhibit TK-HSV-1 (VMW2837) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID68273Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in ESM cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81057Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
AID81050Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50%1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and antiviral activity of 3-substituted derivatives of 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purines, tricyclic analogues of acyclovir and ganciclovir.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		3.08106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytosine
[no description available]		3.0810aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ethylene oxide
Ethylene Oxide: A colorless and flammable gas at room temperature and pressure. Ethylene oxide is a bactericidal, fungicidal, and sporicidal disinfectant. It is effective against most micro-organisms, including viruses. It is used as a fumigant for foodstuffs and textiles and as an agent for the gaseous sterilization of heat-labile pharmaceutical and surgical materials. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p794). oxirane : A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom.		4.2930gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent		allergen;
mouse metabolite;
mutagen
chloroethylene oxide
chloroethylene oxide: postulated metabolite of vinyl chloride; structure		3.520organochlorine compound
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.0410adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
1,n(6)-ethenoadenine
1,N(6)-ethenoadenine: biologically active fluorescent derivatives of this cpd potentially valuable in studies concerning interactions between adenine cpds & various enzymes for which they serve as substrates or co-factors; structure		3.0810imidazo[2,1-i]purinemutagen
1,n(6)-ethenoadenosine
1,N(6)-ethenoadenosine: fluorescent probe; structure		2.0410
5,6,7,9-tetrahydro-7-hydroxy-9-oxoimidazo(1,2-a)purine
5,6,7,9-tetrahydro-7-hydroxy-9-oxoimidazo(1,2-a)purine: derivative of N(2)-(2-oxoethyl)guanine; structure given in first source		1.9910
n(2),3-ethenoguanine
N(2),3-ethenoguanine: formed from 2-halooxiranes. N(2),3-ethenoguanine : A nucleobase analogue obtained by addition of an etheno group across positions N2 and 3 of guanine.		3.0810imidazopurine;
nucleobase analogue
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		1.97102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
deoxyguanosine
[no description available]		2.0410purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanine
[no description available]		3.08102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		4.5240guanosines;
purines D-ribonucleoside		fundamental metabolite
ganciclovir
[no description available]		1.97102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
8-hydroxy-2'-deoxyguanosine
8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.		2.0410guanosinesbiomarker
3,n(4)-ethanocytosine
[no description available]		3.0810organic heterobicyclic compoundmutagen
ConditionIndicatedRelationship StrengthStudiesTrials
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		01.9710